Physician profile
James Son
NPI 1730534199
$76,930.99
in general payments reported to CMS, 2019-2025
17 companies · $61.60 in 2025
The $61.60 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $37K · 2021: $77.07 · 2022: $453 · 2023: $1,868 · 2024: $235 · 2025: $61.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $74,392.12 | 2019-2023 | |
| Abbvie INC. | $669.44 | 2021-2024 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $439.94 | 2022-2024 | Amjevita, Avsola, Enbrel |
| Ucb, INC. | $303.46 | 2022-2024 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $263.82 | 2021-2025 | Orencia |
| Janssen Biotech, INC. | $225.34 | 2022-2024 | Simponi Aria, Stelara, Remicade |
| Novartis Pharmaceuticals Corporation | $179.78 | 2022-2023 | |
| Aurinia Pharma U.S., INC. | $111.04 | 2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $64.52 | 2023 | Strensiq |
| Organon LLC | $58.70 | 2022-2023 | Renflexis, Hadlima |
| Fresenius Kabi USA, LLC | $57.24 | 2023 | Idacio |
| Radius Health, INC. | $51.20 | 2023 | Tymlos |
| Biocon Biologics INC | $28.37 | 2024 | Hulio |
| Sandoz INC. | $27.56 | 2023 | |
| Sobi, INC | $23.86 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $17.56 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.04 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Son listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.